A 300-mg loading dose should be given before or at the time of PCI to patients who did not receive a previous loading dose and who are undergoing PCI within 24 hours of receiving fibrinolytic therapy (Class I, Level of Evidence: C); b. A 600-mg loading dose should be given before or at the time of PCI to patients who did not receive a previous loading dose and who are undergoing PCI more than 24 hours after receiving fibrinolytic therapy (Class I, Level of Evidence: C); and c. A dose of 75 mg daily should be given after PCI.37,38,116,117 (Class I, Level of Evidence: C) (Continued) Appendix A. Continued 29 Appendix A. Continued Clinical Recommendation(s) Continued 2014 AHA/ACC Guideline for the Management of Patients With Non ST-Elevation Acute Coronary Syndromes11 inhibitor (either clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTE-ACS without contraindications who are treated with either an early invasive or ischemia-guided strategy. Options include: Clopidogrel: 300-mg or 600-mg loading dose, then 75 mg daily.33,42 (Class I, Level of Evidence: B) Ticagrelor: 180-mg loading dose, then 90 mg twice daily.7,118 (Class I, Level of Evidence: B) 2. In patients receiving a stent (bare-metal stent or drug-eluting stent [DES]) during PCI for NSTE-ACS, P2Y12 inhibitor therapy should be given for at least Options include: (Class I, Level of Evidence: B) or (Class I, Level of Evidence: B) or Ticagrelor: 90 mg twice daily7 (Class I, Level of Evidence: B) 3. In addition to aspirin, a P2Y12 inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia-guided strategy. 